development and validation of a dissolution test with reversed-phase high performance liquid chromatographic analysis for candesartan cilexetil in tablet dosage forms
Clicks: 210
ID: 228940
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
210 views
30 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #120 of 167 articles by views in Behavioural brain research
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 167 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
A simple, rapid, selective and reproducible reversed-phase high performance liquid chromatographic (RP-HPLC) method has been developed and validated for the estimation of release of Candesartan cilexetil (CC) in tablets. Analysis was performed on an Agilent, Zorbax C8 column (150mm × 4.6mm, 5μm) with the mobile phase consisting of phosphate buffer (pH2.5)–acetonitrile (15:85, v/v) at a flow rate of 1.0mL/min. UV detection was performed at 215nm and the retention time for CC was 2.2. The calibration curve was linear (correlation coefficient = 1.000) in the selected range of analyte. The optimized dissolution conditions include the USP apparatus 2 at a paddle rotation rate of 50rpm and 900mL of phosphate buffer (pH7.2) with 0.03% of polysorbate 80 as dissolution medium, at 37.0 ± 0.5°C. The method was validated for precision, linearity, specificity, accuracy, limit of quantitation and ruggedness. The system suitability parameters, such as theoretical plate, tailing factor and relative standard deviation (RSD) between six standard replicates were well within the limits. The stability result shows that the drug is stable in the prescribed dissolution medium. Three different batches (A, B and C) of the formulation containing 8mg of Candesartan cilexetil was performed with the developed method and the results showed no significant differences among the batches.
| Reference Key |
kamalakkannan2016arabiandevelopment
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Vairappan Kamalakkannan;Ayarivan Puratchikody;Lakshmanan Ramanathan;Sundaravadivelu Jayapraba |
| Journal | Behavioural brain research |
| Year | 2016 |
| DOI |
10.1016/j.arabjc.2011.09.011
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.